Abstract
Breast cancer is a complex, molecular disease, in which a number of cellular pathways involving cell growth and proliferation, such as the MAPK, RB/E2F, P13K/AKT/mTOR, and TP53 pathways, are altered. These pathways represent molecular mechanisms that are composed and regulated by various genes. The genes that are altered in terms of cell growth and proliferation include the oncogenes HER2, c-MYC, and RAS, the ER genes, and the genes for cell cyclin D1 and E, and the tumor suppressor genes RB, TP53, and PTEN, and the breast cancer susceptibility genes BRCA1 and BRCA2. Although the nature of breast cancer is complex and has frustrated previous attempts at treatment or prevention, the elucidation of its molecular nature over the last several decades is now providing targets for effective therapies to treat the disease and hopefully one day to prevent it.
At the beginning of the twentieth century, a number of theories were proposed to account for carcinogenesis (CitationMarcum 2002). Of these, Boveri’s somatic mutation theory became the predominant guiding theory (CitationBoveri 1914; CitationVarmus and Weinberg 1993). The current manifestation of the theory states that cancer is the result of sporadic and/or inheritable genetic mutations in somatic or germinal cells, respectively (CitationEdler and Kopp-Schneider 2005; CitationSchulz 2006; CitationWunderlich 2006). These mutations affect a number of cellular pathways, including the MAPK, RB/E2F, P13K/AKT/mTOR, and TP53 pathways, which are responsible for cell growth and proliferation (CitationHanahan and Weinberg 2000; CitationVogelstein and Kinzler 2004; CitationSchulz 2006).
Malignant breast cancer is a complex, molecular disease in which alterations take place in the genes that govern cell growth and proliferation (CitationSledge and Miller 2003; CitationIngvarsson 2004). The predominant form of breast cancer is sporadic in nature, in which oncogenes – which are initially mutated – lead to uncontrolled cell proliferation (CitationKenemans et al 2004). Other genetic mutations, especially in tumor suppressor genes (TSGs), are then thought to lead to malignancy. Hereditary or familial breast cancer, which represents only 5%–10% of breast cancer cases, is controlled by inheritable mutations to susceptibility genes, among other genes (CitationPavelić and Gall-Trošelj 2001; CitationMargolin and Lindblom 2006; CitationWalsh and King 2007).
The progression from normal to malignant breast tissue is not completely understood today but enough of the process is understood to develop therapies that target the molecular changes that occur during breast carcinogenesis (CitationOsborne et al 2004; CitationSchulz 2006). Traditional chemotherapy for treatment of cancer suffers from two major problems. First, it is non-specific in that the drugs used to treat patients cannot distinguish between tumor and normal cells. This inability to distinguish between the two types of cells leads to a second problem – toxic side effects that are often more debilitating than the disease. A new approach to treatment – targeted therapy – attempts to resolve these problems by the rational design of drugs that specifically target cancer cells (CitationSegota and Bukowski 2004; CitationSeynaeve and Verweij 2004; CitationGarrett 2005; CitationPegram et al 2005; CitationSledge 2005; CitationSharkey and Goldenberg 2006).
Over the past decade, targeted therapy has offered particularly promising means to treat breast cancer (CitationBange et al 2001; CitationSledge 2001; CitationKaklamani and O’Regan 2004; CitationOsborne et al 2004; CitationGasparini et al 2005; CitationHobday and Perez 2005; CitationJohnson and Seidman 2005; CitationTripathy 2005; CitationMuss 2006). In this review, a limited selection of the genes responsible for cell growth and proliferation, including oncogenes, TSGs, and susceptibility genes, are examined and discussed, especially with respect to targeted therapies. The paper concludes with a discussion of the challenges facing basic and clinical research to develop effective and safe treatment of a disease that is estimated to kill 40,460 women in 2007, in the USA alone (CitationJemal et al 2007).
Oncogenes
Oncogenes are the first “cancer” genes to be well studied molecularly and represent alterations of proto-oncogenes that are involved in the normal regulation of cell growth and proliferation (CitationVarmus and Weinberg 1993; CitationMacdonald et al 2004; CitationSchulz 2006). Alteration of these genes results in what is termed gain-in-function, ie, cell growth and proliferation. These genes are responsible for sending the cell from a resting state into cell division. In other words, they are comparable to stepping on the accelerator of an automobile (CitationWeinberg 1998).
Oncogenes are dominant, since a single “hit” or alteration is required to activate them. For example, they may be amplified or their protein products overexpressed and therefore more of the product is present; or, they may be mutated to enhance the function of the protein (CitationOsborne et al 2004; CitationSchulz 2006). They are responsible for sporadic cancers, which account for the majority of breast cancers (CitationMacdonald et al 2004; CitationSchulz 2006). Although oncogenes are involved in the initiation of cancer, they appear not to be as important in the latter stages (CitationHarris 2005). There are a host of oncogenes involved in the development of breast cancer, with HER2, c-MYC, and RAS, being more intensely studied (). Besides these oncogenes, the genes for estrogen receptors (ERs), cyclin D1 and E, and cyclin-dependent kinases 2 and 4/6 are also important in breast cancer formation ().
HER2
The HER2 gene (human epithelial receptor 2, also known as c-neu or c-erbB2) belongs to the HER gene family, with epidermal growth factor receptor (EGFR) or HER1 being the first discovered (CitationRoss and Fletcher 1998; CitationRoss et al 2004a). The HER2 gene is located on chromosome 17q12 (CitationKaptain et al 2001). The HER2 protein is a 185 kDa transmembrane tyrosine kinase growth factor receptor and shares structural homology with the other HER family members, including an extracellular region, a transmembrane region, and a cytoplasmic region (CitationKlapper et al 2000; CitationKaptain et al 2001; CitationJorissen et al 2003; CitationBazley and Gullick 2005). The extracellular region at the amino terminus is glycosylated and contains two ligand-binding domains and two cysteine-rich domains that are critical for receptor dimerization. The hydrophobic transmembrane region makes a single pass through the cell membrane. The cytoplasmic region contains the protein tyrosine kinase domain and six tyrosine residues at the carboxy terminus that are available for phosphorylation.
Around a dozen ligands, including EGF, neu or heregulin, and TGFα, bind to the HER receptor family; however, there is no known ligand specific for HER2 or the receptor is unable to bind a ligand (CitationHarris et al 2003; CitationRoss et al 2004a; CitationBazley and Gullick 2005). Upon ligand binding the receptors form either homodimers or heterodimers and are activated by phosphorylating the cytoplasmic tyrosines. HER2 forms heterodimers, especially with HER1 and HER3, which is responsible for tumor formation (CitationHolbro et al 2003; CitationChan et al 2006). The activated receptor dimers are involved via signal transduction in a variety of cellular pathways, such as MAPK and P13K/AKT/mTOR pathways (CitationBazley and Gullick 2005; CitationChan et al 2006). Functionally, the HER receptor family is involved in cell growth and proliferation, angiogenesis, altered cell-cell interactions, increased cell motility, metastasis, and resistance to apoptosis (CitationOsborne et al 2004; CitationSunpaweravong and Sunpaweravong 2005).
The HER2 gene is amplified in 20%–30% of breast cancer cases or the HER2 protein is overexpressed in roughly the same percentage of cases, although there are cases in which the protein is overexpressed while the gene is not amplified (CitationBerns et al 1995; CitationKaptain et al 2001; CitationRoss et al 2003; CitationHudis 2007; CitationMagnifico et al 2007). HER2 overexpression is found almost exclusively in breast cancer of ductal origin rather than lobular origin (CitationKlapper et al 2000; CitationRoss et al 2004a). It is also associated with higher recurrence rates and lower response to chemotherapy or hormone therapy, with overall poor prognosis and survival (CitationKaptain et al 2001; CitationRoss et al 2004a). Moreover, 15% of breast cancer cases expressed lower levels of the HER2 protein than normal breast tissues and exhibited higher grade tumors than cases in which the protein is overexpressed (CitationTovey et al 2006). Overexpression of other members of the HER family is also observed in breast cancer cases, with HER1, HER3, and HER4 overexpressed in 16.4%, 17.5%, and 11.9% of the cases, respectively (CitationWitton et al 2003). Interestingly overexpression of HER4 conferred an increased survival rate, although the reason for this phenomenon is unclear and requires further evidence to support it.
Given its prominence in the activation of around a half dozen genetic pathways involved in cell growth and proliferation HER2 is a major focus of research in terms of targeted therapy, including monoclonal antibodies, kinase inhibitors, and antisense oligonucleotides (CitationOsborne et al 2004; CitationRoss et al 2004a; CitationHobday and Perez 2005). Trastuzumab is the most celebrated monoclonal for breast cancer treatment, first tested in clinical trials in the mid to late 1990s (CitationBaselga et al 2006; CitationPiccart-Gebhart 2006; CitationHudis 2007; CitationNahta and Esteva 2007). It is a humanized monoclonal antibody, originally produced in mice, which recognizes the extracellular domain. It is particularly effective in patients who overexpress HER2, with response rates ranging from 12% to 34%, and is commonly used in conjunction with chemotherapy or at least one cytotoxic drug except anthracycline (due to cardiomyopathy). Trastuzumab binds to HER2 and works through multiple mechanisms, including, for example, inhibition of heterodimer formation, potentiation of chemotherapy, and enhanced cell apoptosis.
Pertuzumab is another monoclonal antibody that inhibits the formation of heterodimers by recognizing an extracellular region distinct from trastuzumab and is currently being tested clinically (CitationCox et al 2006; CitationMeric-Bernstam and Hung 2006; CitationWalshe et al 2006). It may be effective in combination therapy with agents such as trastuzumab. Lapatinib is a large-head group quinazoline, reversible inhibitor of the tyrosine kinase domain of HER1 and HER2 (CitationBurris 2004; CitationMeric-Bernstam and Hung 2006). Preliminary data from clinical trials reveal that 8% of refractory metastatic breast cancer patients have a complete response to the inhibitor (CitationMoy and Goss 2006). Moreover, lapatinib is particularly effective in combination with either capecitabine or trastuzumab, eg, the average time to progression was 8.4 months for the combination of lapatinib and capecitabine but only 4.4 months for capecitabine alone (CitationGeyer et al 2006; CitationKonecny et al 2006). Antisense oligonucleotides to various HER2 domains also offer promise for breast cancer targeted therapy, by downregulating HER2 expression and by sensitizing breast cancer cells to chemotherapy (CitationYang et al 2002, Citation2003).
c-MYC
The c-MYC gene, the cellular homolog to the viral oncogene v-MYC, is located on chromosome 8q24 (CitationRyan and Birnie 1996; CitationJamerson et al 2004). The c-MYC gene product is a nuclear phosphoprotein, with three isoforms: c-MYC1, c-MYC2, and c-MYCS (CitationHenriksson and Luscher 1996; CitationLiao and Dickson 2000; CitationPelengaris and Khan 2003; CitationJamerson et al 2004). The predominant isoform is c-MYC2, which is a 62 kDa protein. Its amino terminus contains the MYC box I and box II elements responsible for transcriptional regulation, while its carboxy terminus contains basic, helix-loop-helix and leucine zipper motifs that are involved in DNA binding and in heterodimerization with the transcription factor MAX. The heterodimer MYC-MAX binds to the E box (CACGTG) regulatory element of growth-related genes thus inducing transcription. c-MYC1’s amino terminus is slightly extended, while c-MYCS’s amino terminus is truncated and missing MYC box I.
c-MYC is normally expressed only during cell division and accelerates the cell’s entry into the S phase of the cell cycle, especially through induction of cyclin E-CDK2 activity (CitationPelengaris and Khan 2003; CitationDang et al 2006). The c-MYC gene product functions as a nuclear transcription factor that is involved in the regulation of an extensive network of genes that represents around 15% of human genes. These genes are responsible for a variety of cellular processes, including proliferation, apoptosis, differentiation, and metabolism (CitationOster et al 2002; CitationPelengaris and Khan 2003; CitationJamerson et al 2004; CitationDang et al 2006). Interestingly, c-MYC not only stimulates cell proliferation but also cell apoptosis. To date, this paradox is not fully understood or explained (CitationPelengaris and Khan 2003; CitationDang et al 2006). c-MYC also exhibits dual function, in terms of both transactivation and transrepression of transcription. Transactivation requires the presence of MYC box I, while transrepression MYC box II.
Meta-analysis of the published literature reveals that c-MYC is overexpressed three-fold or greater in 1%–94% of breast cancer cases, with an average of 15.5% (CitationLiao and Dickson 2000). Although there is also considerable variation in the oncogene’s amplification, from 4% to 52%, cases that contain amplified MYC exhibit poor prognosis (CitationGuerin et al 1988; CitationLiao and Dickson 2000; CitationOsborne et al 2004). The overexpression of c-MYC often precedes gene amplification and may result from enhanced transcript or protein stability (CitationLiao and Dickson 2000). Interestingly, amplification of c-MYC is positively correlated with amplification of HER2 (CitationGaffey et al 1993; CitationLiao and Dickson 2000). Although there is consensus concerning the role of c-MYC in breast carcinogenesis, most researchers agree that other genes are also required. For example, c-MYC-induced breast cancer is correlated with spontaneous KRAS2 mutation (CitationD’Cruz et al 2001).
Use of antisense oligonucleotides to specific regions of c-MYC demonstrates that the expression of the oncogenic protein and proliferation of cells overexpressing the oncogene are significantly reduced by 30% (CitationWatson et al 1991; CitationCarroll et al 2002). However, application of antisense technology has not been unproblematic. Recently, RNA interference technology has been developed to silence gene expression in mammalian cells (CitationSui et al 2002). Briefly, dsRNAs are used to generate short interfering RNAs (siRNAs) that are incorporated into a nuclease complex that binds specifically to the targeted mRNA and cleaves it. Knockdown of c-MYC in a breast cancer cell line using a short hairpin transcript corresponding to c-MYC mRNA nt 1906–1926, resulted in an 80% reduction in c-MYC gene expression (CitationWang et al 2005). Also, tumor generation in nude mice was inhibited for two months. Finally, use of a triplex-forming oligonucleotide to bind duplex DNA resulted in around 40% reduction of c-MYC expression in breast cancer cells (CitationChristensen et al 2006). These approaches are heralded to provide future benefits for targeting breast cancer therapeutically.
RAS
The RAS genes are located on three separate chromosomes (CitationGiehl 2005). The first is on chromosome 11p15.5 and transcribes HRAS kinase. The next gene is on chromosome 12p12.1 is responsible for two splicing variants, KRAS4A and KRAS4B. The final gene is on chromosome 1p13.2 and encodes for NRAS kinase. The RAS kinases are members of a superfamily of 21 kDa monomeric GTPases (CitationGiehl 2005; CitationSchulz 2006). The kinases contain three domains, with two highly conserved catalytic domains. The third is located at the carboxy terminus and is a cell membrane targeting domain that is highly variable, which is composed of a linker region that contains nuclear trafficking signals and an anchor region that connects the protein to the cell membrane (CitationGiehl 2005). During posttranslational modifications, the anchor region undergoes prenylation of a CAAX motif (C stands for cysteine, A for an aliphatic amino acid, and X for any amino acid) and then palmitoylation of two cysteines for HRAS and one cysteine for NRAS and KRAS4A (CitationHancock 2003; CitationO’Regan and Khuri 2004; CitationGiehl 2005). KRAS4A is not palmitoylated but contains six contiguous lysines. The modified RAS kinases are then embedded in the cytoplasmic side of the plasma membrane.
The RAS kinases are activated through binding of growth factors to receptors, like the receptor tyrosine kinases (CitationGiehl 2005; CitationSchulz 2006). Activation occurs with the exchange of GTP for GDP. The activated RAS protein then phosphorylates a number of secondary messengers involved in a variety of cellular pathways that function in cell apoptosis, differentiation, motility, and proliferation. One of the more important pathways is the RAF/MEK/ERK pathway, which is one of several MAPK pathways (CitationSchulz 2006). RAS phosphorylates the RAF serine/threonine kinases, which in turn phosphorylate the MEK 1 and 2 kinases, which in turn phosphorylate ERK 1 and 2. Phosphorylated ERK translocates to the nucleus, where it interacts with various transcription factors involved in cell proliferation. Another important pathway is the P13K/AKT/mTOR pathway. RAS phosphorylates P13K, which in turn phosphorylates phosphatidyl inositol resulting in the production of PIP3. PIP3 is a second messenger that is involved in the activation of other downstream molecules, such as the kinase AKT and mTOR. Activation of this pathway results in cell survival through the inhibition of cell apoptosis.
Analysis of breast tumors demonstrates that RAS is only associated with less than 5% of breast cancer cases (CitationClark and Der 1995; CitationEckert et al 2004). Moreover, in those cases in which it participates the oncogene appears not to be mutated as is the case in other RAS tumors (CitationEckert et al 2004). Rather, RAS is hyperactive because of overexpression of EGF and/or HER2 (CitationStevenson et al 1999; Citationvon Lintig et al 2000; CitationEckert et al 2004). However, those cases that involve RAS exhibit poor prognosis (CitationField and Spandidos 1990). Analysis of breast cancer cell lines, on the other hand, reveals RAS gene mutations (Citationvon Lintig et al 2000; CitationHollestelle et al 2007). Point mutations are observed in 7 of 40 cell lines, with the preponderance of mutations in KRAS (CitationHollestelle et al 2007). Recently, the effector pathway(s) for cell apoptosis in breast cancer may not be the RAF/MEK/ERK or the P13K/AKT/mTOR pathways but another, such as the Ral or Rac pathways (CitationEckert et al 2004). A modified breast cancer cell line in which HRAS and NRAS are constitutively expressed reveals that HRAS activation of the Rac-MKK3/6-p38 pathway may play a role in breast cancer metastasis (CitationShin et al 2005).
RAS offers several molecular targets for therapeutic intervention. The first step in RAS activation involves the transfer of a prenyl group to RAS by farnesyl transferase. A number of inhibitors to the enzyme have been shown to inhibit its activity and thereby to inhibit the growth of a number of tumor lines (CitationHead and Johnston 2004; CitationO’Regan and Khuri 2004). The first generation of inhibitors, such as L-744,832 and FTI-277, were successful and eventually led to a second generation of inhibitors, R115777 and SCH66336. In preclinical trials, R115777 inhibits by up to 85% the proliferation of breast cancer cell lines in vitro and growth of tumors in vivo (CitationWärnberg et al 2006). Phase II trials demonstrated limited clinical efficacy of R115777 in treating cases of advanced breast cancer, with 10% of patients having a partial response (CitationJohnston et al 2003). Recently clinical trials are underway to examine the synergistic effects of farnesyl transferase inhibitors with other drugs, such as tamoxifen or the taxanes (CitationHead and Johnston 2004; CitationLebowitz et al 2005). Similar trials are underway with SCH66336 (CitationBasso et al 2005; CitationMarcus et al 2005). Antisense oligonucleotides are also promising, especially when combined with other drugs (CitationAdjei et al 2003).
Cyclins D1 and E
The cell cycle is composed of a variety of phases that result in cell growth and replication (CitationSchafer 1998; CitationIsraels and Israels 2000). Cells in the quiescence G0 phase are shuttled into the G1 phase in which they prepare to enter the S phase of DNA replication. After the S phase, the cells enter the G2 phase prior to mitosis or the M phase, during which the cells undergo division. The cell cycle and its various phases are closely regulated in a dynamic fashion, by a variety of factors (CitationTyson et al 2002). The first are the cyclin-dependent kinases (CDKs), which are the “engines” that power cell cycle events (CitationMorgan 1997). They constitute a family of serine/threonine protein kinases, with around a dozen members of which around half are involved in the cell cycle. While the levels of CDKs do not oscillate during cell cycle events, cyclins, which bind and activate the CDKs, do and provide one level of regulation (\CitationJohnson and Walker 1999; CitationMurray 2004). Another level of regulation involves CDK inhibitors (CKIs), of which there are a little over a half-dozen divided into two families, INK4 and Cip/Kip families (CitationSoos et al 1998). CKIs are critical for inactivating CDK/cyclin holoenzymes. Interestingly, recent gene targeted studies on mouse development challenge the standard “CDK-centric” paradigm (CitationSherr and Roberts 2004; CitationMalumbres 2005; CitationSánchez and Dynlacht 2005).
A key junction in the regulation of the cell cycle vis-à-vis carcinogenesis is the transition from the G1 to the S phase (CitationSherr 1996, Citation2000; CitationSandal 2002; CitationPark and Lee 2003). Cyclins D1 and E, the G1 cyclins, are critical regulatory elements in the transition of the cell from the G1 phase to the S phase. Cyclin D1 is upregulated by growth factors, like EGF and estrogen, and binds to CDK4/6 and partially phosphorylates RB, which in turn releases E2F. E2F is a transcription factor that targets the cyclin E gene and upregulates it. The cyclin E gene product binds to CDK2 and forms the cyclinE-CDK2 holoenzyme, which then completes the phosphorylation and inactivation of RB. RB is the “master switch” that is responsible for turning on or off the cell cycle (CitationSherr 1996, Citation2000). Finally, the CKIs p21 and p27 also play an important regulatory role in the transition from G1 to S (CitationSherr and Roberts 1999). Cancer, including breast cancer, is then a result of deregulation of the genes involved in cell cycle control (CitationLodén et al 2002; CitationVermeulen et al 2003; CitationSutherland and Musgrove 2004; CitationCaldon et al 2006).
The cyclin D1 gene, CCND1 (PRAD1), is located on chromosome 11q13 and is composed of five exons (CitationFu et al 2004). It encodes for a 34 kDa protein that contains several domains (CitationArnold and Papanikolaou 2005). At the amino terminus is a RB binding domain. Cyclin D1 also contains a highly conserved cyclin box, which is composed of around 100 amino acids and is responsible for binding CDKs. A common polymorphism (A/G) is located at 870 nt and is associated with a slicing variant of cyclin D1, which contains intron 4 but in which exon 5 is deleted. Cyclin D1 is overexpressed in greater than 50% of breast cancer cases but its gene is only amplified in 13%–20% of breast cancer cases (CitationArnold and Papanikolaou 2005; CitationRoy and Thompson 2006). When cyclin D1 is overexpressed it shortens the time spent in G1 and allows more cells to enter the S phase, which relies on both CDK-dependent and CDK-independent mechanisms. Its overexpression is associated with an aggressive form of breast cancer and poor prognosis. The cyclin D1 gene is co-amplified with the HER2 and c-MYC genes and is associated with ER positivity. To date, there are no targeted therapies based on cyclin D1, although it is believed to hold great promise for future therapeutic intervention (CitationArnold and Papanikolaou 2005).
The cyclin E gene is located on chromosome 19q12 and encodes for a 50 kDa protein, along with almost a dozen splicing variants – some of which are incapable of activating CDK2 (CitationMöröy and Geisen 2004). Cyclin E possesses the conserved cyclin box for CDK2 binding, as well as a CKI binding site. In addition it contains specific proteolytic sites at the amino terminus that are sensitive to elastase degradation, generating five isoforms that exhibit greater holoenzyme activity than the native isoform (CitationAkli and Keyomarsi 2003; CitationHarwell et al 2004; CitationHunt and Keyomarsi 2005). Interestingly, these elastase-generated isoforms are only found in cancer cells and not in normal cells. Although cyclin E is overexpressed in breast cancer, by as much as 64-fold in some breast cancer cell lines, it is rarely amplified and is not overexpressed when cyclin D1 is overexpressed (CitationLodén et al 2002; CitationHunt and Keyomarsi 2005). Cyclin E overexpression is associated with poorly differentiated tumors and ER negativity; however, it also reduces infiltrative growth of breast carcinoma (CitationBerglund and Landberg 2006). Its overexpression is also associated with genomic instability (CitationAkli and Keyomarsi 2004; CitationMöröy and Geisen 2004). Cyclin E has yet to be developed in terms of targeted therapy, although preliminary studies with elatase inhibitors appear promising (CitationAkli and Keyomarsi 2003; CitationHunt and Keyomarsi 2005).
Besides cyclins, CDKs have also been a target for therapeutic development (CitationSenderowicz 2003; CitationVermeulen et al 2003; CitationOsborne 2004; CitationCollins and Garrett 2005). Two approaches are taken: a direct approach in which CDKs’ catalytic sites, especially the ATP-binding site, are targeted and an indirect approach in which the upstream pathways that govern CDKs are targeted. For the direct approach a number of small molecular weight inhibitors have been developed that are specific for particular CDKs, such as roscovitine, purvalanol, and nitrosopirimidines, which target CDK1, 2, and 5, and indolocarbazoles and PD0183812, which target CDK4, and flavopiridol and UCN-01, which target CDKs nonspecifically. For example, roscovitine inhibits by 50%–70% the proliferation of human breast carcinoma cells (CitationWęsierska-Gądek et al 2003). A number of strategies have been developed for the indirect approach, including the overexpression of endogenous CKIs through gene therapy and small molecular weight molecules like lovastatin and rapamycin, the depletion of cyclins and CDKs through antisense oligonucleotides and small molecular weight molecules like tamoxifene and the retinoids, and the modulation of the proteasome mechanism like PS341. For example, lovastatin at 50 μM inhibits the proliferation of human breast cancer cell line MCF-7, by up to 90% (CitationSeeger et al 2003). Overall, these approaches are in various stages of clinical trials and use, with varying degrees of efficacy and safety.
Estrogen and its receptor
Estrogen is a generic term for a family of sex hormones that are critical for the mammalian estrous cycle (CitationMessinis 2006). There are three main classes of estrogens: estradiol (17β-estradiol), estrone, and estriol. Estrogen synthesis takes place predominantly in the ovaries in premenopausal women and to a lesser extent in extragonadal tissues, including breast tissue, which, along with other extragonadal tissue, is its source in postmenopausal women (CitationHuang et al 2005; CitationJordan and Brodie 2007). It begins with the synthesis of C-19 androgens from cholesterol in ovarian theca interna cells. Upon entrance into ovarian granulosa cells the androgens are aromatized by an aromatase complex, consisting of cytochrome P450 hemoprotein and NADPH-cytochrome P450 reductase – a flavoprotein that is part of a larger cytochrome superfamily. Three hydroxylation steps are postulated in the synthesis of estradiol from testosterone and of estrone from androstenedione. Finally, estrogens appear to enhance their own synthesis through a feed-forward mechanism involving prostaglandin synthesis (CitationFrasor et al 2003).
There are two types of estrogen receptors (ERs), which are the product of two separate genes (CitationKenemans et al 2004). The ERα gene is located on chromosome 6q25.1, while the ERβ gene is located on chromosome 14q22–24. Although there are two different ER genes, their products share considerable structural and functional homology (CitationKuiper et al 1996). Both ERs contain six structural domains (domains A–F) that compose several functional domains (CitationHerynk and Fuqua 2004). A transactivation domain is associated with amino terminus domains A and B, which bind various regulatory elements that modulate ER-mediated transcriptional activity. A DNA binding domain is associated with domain C, which contains two zinc finger motifs. This domain binds to the promoters of ER-targeted genes. The ER dimerization domain is divided between the C and E domains, along with an area at the carboxy terminus. The nuclear localization signal is located in domain D, which also contains the hinge region. Finally, domains E and F contain a ligand-binding domain and another transactivation domain. Both ERs also exhibit a variety of splicing variants (CitationHerynk and Fuqua 2004).
Estrogen is a potent mitogenic hormone that is critical not only in breast development but also in its carcinogenesis, although there is debate about its role in breast cancer initiation (CitationFoster et al 2001; CitationWren 2004; CitationRusso and Russo 2006). The ERα isoform is the predominant agent of mitogenic activity in breast tissue and is overexpressed in the early stages of breast cancer (CitationHayashi et al 2003; CitationHewitt et al 2005). Around two-thirds of breast cancer tissue expresses higher ER levels than normal tissue (CitationIdeka and Inoue 2004). Estrogen binds to ERα to form a stable receptor dimer that is then phosphorylated inducing a conformational change, which thereby exposes a DNA-binding domain and transcriptional activation domains (CitationButt et al 2005). The dimer binds to target genes involved in phosphorylation of RB, especially both c-MYC and cyclins D1 and E (CitationRoy and Thompson 2006).
Growth factors, such as EGF, IGF-I, and TGFα, also bind ER and lead to mitogenic activity in breast cancer cells (CitationButt et al 2005). ER and HER2 pathways also share contact or “cross-talk” during breast tumorigenesis (CitationSledge and Miller 2003). The role of ERβ in the development of breast cancer is unclear, although the ratio of ERα to ERβ is important in breast carcinogenesis (CitationCullen et al 2001; CitationHerynk and Fuqua 2004). Finally, breast cancer tissue can be either ER-positive or ER-negative, with the ER-positive tumors forming a unique molecular subgroup (CitationPerou et al 2000). ER-negative tumors are associated with an aggressive form of the disease and consequently with poor prognosis (CitationRochefort et al 2003).
Antihumoral therapy is composed of antiestrogens to counteract the effects of estrogens on breast tissue, especially as antagonists to ERs (CitationHuang et al 2005; CitationGao and Liu 2007). Type I antiestrogens, also known as selective estrogen receptor modulators (SERMs), are non-steroidal inhibitors, including tamoxifen, toremifene, and raloxifene. These antiestrogens are widely used because they do not bind ERs indiscriminately; rather, they are partially selective in their binding specificity and thereby protective against estrogen-associated bone loss (CitationJordan 2007). Type II antiestrogens include antagonists that are steroidal derivatives of estrogen, eg, ICI 164,384 and ICI 182,780. The binding of both types of antiestrogens causes a conformational change in ER’s carboxy terminus. Unfortunately many patients become resistant to antiestrogen therapy. The mechanism of resistance is not completely understood; but the standard protocol is to switch to an estrogen-deprivation therapy, such as aromatase inhibitors (CitationHuang et al 2005).
The aromatase complex represents an attractive target for therapeutic development, since the synthesis of estrogen represents the final step in its synthetic pathway. Consequently, estrogen synthesis can be specifically inhibited without compromising the synthesis of other sex hormones (CitationJordan and Brodie 2007). However, the role of estrogens in other tissues besides breast cancer tissue makes the use of these inhibitors problematic since they create a “no estrogen state” (CitationHuang et al 2005; CitationJordan and Brodie 2007). Aromatase inhibitors (AIs) represent a very successful targeted therapy for breast cancer in postmenopausal women (CitationAltundag and Ibrahim 2006).
There are two types of AIs, which are currently in their third generation (CitationHuang et al 2005; CitationAltundag and Ibrahim 2006). Type I inhibitors, such as exemestane, mimic the binding of the androgen substrate and thereby bind covalently and irreversibly to aromatase. Type II inhibitors, such as letrozole, are non-steroidal in nature and bind irreversibly to aromatase’s catalytic site. Recent studies demonstrate that AIs are effective as or even more effective than tamoxifen and are being administered as the primary adjuvant therapy instead of using it after tamoxifen as previously done (CitationAltundag and Ibrahim 2006). For example, letrozole was better in clinical studies than tamoxifen with respect to time to treatment failure, 9.4 months versus 6.0 months on average respectively (CitationMouridsen et al 2003).
Tumor suppressor genes
While in general oncogenes promote cell growth and proliferation, tumor suppressor genes (TSGs) inhibit them (CitationVarmus and Weinberg 1993; CitationMacdonald et al 2004; CitationSchulz 2006). Alteration of these genes results in what is termed loss-of-function, ie, cell quiescence, which leads to cell growth and proliferation. These genes are responsible for stopping the cell from dividing during cell division, especially if DNA is damaged during its replication (CitationMotoyama and Naka 2004). In other words, they represent stepping on the brake of an automobile (CitationWeinberg 1998).
In stopping cell division, TSGs also maintain the integrity of the cell’s genome and therefore function as a competent automobile mechanic (CitationVogelstein and Kinzler 2004). Because of their functions in stopping the cell from dividing or in ensuring the DNA is not damaged, TSGs are often called gatekeepers or caretakers, respectively (CitationKinzler and Vogelstein 1997; CitationMacLeod 2000). As such, they are important in maintaining the genome’s stability and integrity (CitationSherr 2004).
TSGs are recessive and require two “hits” in order to inactivate them (CitationKnudson 1971). For example, they may be deleted physically or lost via recombination; or, they may be mutated or their promoter hypermethylated (CitationSchulz 2006). TSGs are responsible for many hereditary cancers, such as the eye tumor retinoblastoma, although they are also necessary for the development of sporadic cancers (CitationMacdonald et al 2004; CitationSchulz 2006). Because of their role in hereditary cancer, they are called susceptibility genes and act in a dominant fashion (CitationMacdonald et al 2004). There are several TSGs involved in the development of breast cancer, including RB, TP53, and PTEN, and the susceptibility genes BRCA1 and BRCA2 (). In general, treatment development based on TSGs presents a greater challenge than that based on oncogenes because TSGs represent loss-of-function rather than gain-of-function.
RB
The retinoblastoma (RB) gene is located on chromosome 13q14 and is made up of 27 exons (CitationWhyte 1995; CitationClaudio et al 2002; CitationMacdonald et al 2004; CitationDu and Pogoriler 2006). The gene product, RB or p105, is a 105 kDa nuclear phosphoprotein, which contains no catalytic site and binds weakly and non-specifically to DNA. It contains well over a dozen possible phosphorylation sites, especially within the amino and carboxy termini. The RB protein shares conformational homology with RBL1 or p107, located on chromosome 20q11, and with RBL2 or p130, located on chromosome 16q12. This protein family is called the “pocket” proteins, since they contain a highly conserved pocket region for binding cellular proteins. RB protein contains an A domain (exons 11–17) and a B domain (exons 20–23), separated by a short spacer (exons 18 and 19). The A/B domain makes up the small pocket region and, along with the carboxy terminus, makes up the large pocket region. These regions are responsible for binding various proteins and have at least two protein binding sites, one for E2F proteins (A/B domain interface) and another for proteins containing an LXCXE motif (B domain), which are functionally distinct from one another (CitationChau et al 2006). The spacer between the A and B domains for RBL1 and RBL2 binds cyclins A and E, while the PB spacer is too short to bind proteins.
The RB protein binds over 110 cellular proteins that can be divided into three classes (CitationMorris and Dyson 2001). The first includes kinases, and their regulators, and phosphatases, the next class transcriptional regulators, and the final class miscellaneous proteins that are involved in disparate functions such as cell cycle regulation and DNA replication. These proteins function to limit cell growth and proliferation, to amplify cell differentiation, and to restrain cell apoptosis (CitationMorris and Dyson 2001; CitationZheng and Lee 2001; CitationKnudsen and Knudsen 2006). The most well studied protein that binds to the large pocket of RB belongs to the transcriptional regulator E2F family, which makes up the RB/E2F pathway (CitationDyson 1998; CitationMacdonald et al 2004). The E2F family consists of eight family members, divided into four groups (CitationDu and Pogoriler 2006). The first consists of E2F1-3 and is called the “activating E2Fs,” since members of this class bind preferentially to RB and are responsible for promoting cell division. The second class consists of E2F4 and 5 and is called “repressive E2Fs,” since its members bind preferentially to RBL1 and 2 and inhibit cell division. The E2F family binds to the two members of the DP family to form a heterodimer that then binds preferentially to RB family members.
RB or its pathway is altered in roughly 80% of human cancer cases, making it a very important factor in carcinogenesis (CitationSchultz 2006). Loss of RB activity is present in about one-third of sporadic breast cancer cases and has a negative impact on patient outcome and response to treatment (CitationRoss et al 2004b; CitationBosco et al 2007). RB loss in breast cancer occurs from chromosomal deletion, functional inactivation through cyclins A or E overexpression, intragenic mutation, and transcriptional silencing such as promoter hypermethylation (CitationOesterreich and Fuqua 1999; CitationBièche and Lidereau 2000; CitationOliveira et al 2005). Interestingly, 20% of breast cancer cases contain truncated mutations of RB1CC1, an upstream regulator of RB expression (CitationChano et al 2002). Although RB alteration is important in breast cancer, studies with mammary epithelial cells revealed that alterations in other genes like TP53 are also required for tumor initiation and progression (CitationSimin et al 2004). To date, no targeted therapies for RB alterations have been developed, although reintroduction of RB into breast cancer cells resulted in growth suppression (CitationStoff-Khalili et al 2006). And finally, RB modifies the response of breast cancer cells to tamoxifen chemotherapy because of E2F deregulation, resulting in earlier recurrence (CitationBosco et al 2007).
TP53
The TP53 gene is located on chromosome 17p13 and spans 20 kb (CitationMacdonald et al 2004; CitationLacroix et al 2006; CitationSchultz 2006). It is composed of 11 exons, which encode for a 2.8 kb transcript. Its protein product, p53, is a 53 kDa phosphoprotein, although its calculated mass in around 44 kDa. It is generally found in the nucleus and has a rather short half-life of around 20 minutes. p53 belongs to a protein family composed of two other proteins, p63 and p73, both of which share homology with p53 but have different functions. It is a transcriptional activator and exhibits a structure typical to other activators, with three domains. The amino terminal transactivation domain contains a relatively large number of acidic amino acids and proline-rich region, which is responsible for its apoptotic activity. The central core domain of p53 is highly conserved evolutionarily and is responsible for p53’s binding to promoters, during transcriptional activation. It is hydrophobic in nature and is folded into β sheets. The carboxy terminal domain contains many charged amino acids making it hydrophilic in nature. It is responsible for forming p53 tetramers. It also contains three nuclear localization signals.
p53 is responsible for a variety of functions within the cell’s economy, including cell cycle arrest and promotion of apoptosis, DNA repair, cell differentiation, and inhibition of angiogenesis (CitationBraithwaite et al 2005; CitationToledo and Wahl 2006; Vousden and Lane 2007). Its main function is to ensure that the cell’s genome remains intact before cell division occurs and because of this function it is often called the “Guardian of the Genome” (CitationLane 1992). MDM2 (an ubiquitin ligase mouse double minute-2 homologue; called HDM2 in humans) and MDM4, which bind to the amino terminus of p53, are responsible for inhibiting p53 and promoting its degradation (CitationHaupt 2004). p53 also binds to genes such as BAX that are responsible for the apoptotic pathway, thereby shuttling the cell into programmed cell death. The p53 pathway is generally activated by DNA damage, which results in phosphorylation of p53 by ATM or CHK2 at sites near MDM2 and MDM4 binding. MDM2 or MDM4 are released, and the CKI p21 then binds to p53 (CitationMacdonald et al 2004). p21 is transactivated and arrests the cell cycle until the DNA is repaired. Mutations of p53 that disrupt this pathway result in cell division, even though its DNA is damaged. Such damage can lead to carcinogenesis.
Alteration in TP53, usually in terms of missense mutations is found in more than half of all cancers (CitationMacdonald et al 2004; CitationBraithwaite et al 2005). Around 20%–40% of breast cancers have a genetic or an epigenetic altered form of the TP53 gene, which is associated with poor prognosis (CitationGasco et al 2002; CitationBørresen-Dale 2003; CitationMacdonald et al 2004). Usually, the genetic alteration is often a point mutation that results in a malfunctioning, non-degradable protein that accumulates in tumor cells. Altered TP53 (exons 5–8) is generally associated with sporadic breast cancer; however, it may function as a susceptibility gene in patients suffering from Li-Fraumeni syndrome (CitationMacdonald et al 2004; CitationLacroix et al 2006).
An increased rate of TP53 mutation is also associated with carriers of BRCA1 and BRCA2 germline mutations (CitationGasco et al 2002; CitationLacroix et al 2006). BRCA1 apparently stimulates transcription of TP53 since mutant forms of BRCA1 do not have the same activity levels. Apoptosis stimulating protein of p53 (ASPP) increases p53-dependent induction of apoptosis target genes, such as BAX (CitationGasco et al 2002). Finally, alteration of genes in the TP53 pathway can also lead to breast cancer. For example, loss of the cell cycle checkpoint kinase CHK2 results in an inability to stabilize p53 (CitationOsborne et al 2004). However, these mutations are much less common in breast cancer (CitationGasco et al 2002). Downregulation of this gene affords cells with damaged DNA a greater chance of surviving and dividing (CitationIngvarsson 2004).
TP53 and its regulation by MDM2 and MDM4, as well p53 itself, are targets for the development of rational cancer therapies (CitationBraithwaite et al 2005; CitationBouchet et al 2006; CitationLacroix et al 2006). The disruption of MDM2-p53 and MDM4-p53 interactions is targeted through small molecular weight molecules, such as the nutlins, which are cis-imidazoline derivatives. Nutlins have yielded impressive results in xenografts by inhibiting tumor growth at high doses, with no obvious toxicity. Antisense oligonucleotides to the MDM2 gene have also been developed to downregulate the inhibitor, thereby increasing p53 levels. In addition, MDM2 siRNA has been successfully used to inhibit p53-dependent breast cancer (CitationLiu et al 2004). Gene therapy to replace wild type TP53, using retroviruses and the adenovirus Ad5CMv-p53, has been developed to restore p53 functional levels. Finally, restoring or rescuing aberrant p53 activity has proven a successful therapeutic strategy (CitationTakimoto et al 2002; CitationBossi and Sacchi 2007). For example, CP-31398 and PRIMA-1 have been shown to rescue p53 activity by binding to defective p53 and then restoring its ability to function normally (CitationWang et al 2003). Moreover, these agents act synergistically. For example, PRIMA-1 and cisplatin act synergistically to enhance tumor cell apoptosis (CitationBykov et al 2005).
PTEN
The PTEN (phosphatase and tensin homolog deleted on chromosome ten, also known as MMAC1 or TEP1) gene is located on chromosome 10q23.1 (CitationLi et al 1997; CitationWeng et al 1999). It consists of nine exons and transcribes a 5.5 kb mRNA, which encodes for a 53 kDa protein (CitationKim and Mak 2006). The PTEN protein contains a phosphatase domain at the amino terminal region, with a phosphatase motif (HCX(A/X)GXXR(S/T)G) that is common for both tyrosine and dual-specificity (serine and threonine) phosphatases (CitationLi et al 1997; CitationSimpson and Parsons 2001). The catalytic region consists of a wider pocket than most phophatases and contains three positively charged amino acids that account for its preference for acidic substrates (CitationDi Cristofano and Pandolfi 2000). The main substrate for the phosphatase is PIP3 (CitationMaehama and Dixon 1999). The carboxy terminal region consists of a C2 domain that binds phospholipids and of a tail region that contains PEST sequences and CK2 phosphorylation sites important for structural stability and catalytic activity (CitationSimpson and Parsons 2001). Finally the tail region contains a PDZ domain that binds MAGI proteins, which are important for locating the phosphatase at the cell membrane.
PTEN functions in the cell’s economy through arresting the cell cycle and promoting cell apoptosis, as well as regulating cell adhesion, migration, and invasion especially through extracellular molecules like the integrins (CitationTamura et al 1999; CitationDi Cristofano and Pandolfi 2000; CitationWaite and Eng 2002). The PTEN phosphatase acts as a TSG by dephosphylating PIP3, thereby downregulating AKT (also known as protein kinase B). Inhibition of AKT activation in turn downregulates the signal transducer or effector mTOR (mammalian target of rapamycin), which in turn leads to arrest of the cell cycle at G1 and to programmed cell death (CitationLu et al 1999; CitationGuertin and Sabatini 2005; Bianco et al 2006). Besides the cytoplasm, PTEN is also found in the nucleus and may function in not only downregulating the AKT/mTOR pathway but also other cellular pathways like CENP-C and RAD51 pathways that are important in chromosome integrity (CitationChung et al 2006; CitationBaker 2007). Finally, PTEN is also involved in the downregulation of cyclin D1 through the MAPK pathway.
PTEN is involved in germ-line mutations that are responsible for Cowden and Bannayan-Riley-Ruvalcaba syndromes, in which 80% of the tumors arising in these syndromes are present in the breast (CitationLiaw et al 1997; CitationMarsh et al 1998; CitationLu et al 1999). Loss of PTEN is associated with aggressive breast malignancy and poor prognosis (CitationGarcia et al 1999; CitationPetrocelli and Slingerland 2001). PTEN in Cowden breast cancer is chiefly mutated within the amino terminal phosphatase domain, while PTEN in Bannayan- Riley-Ruvalcaba breast cancer is mutated in the non-phosphate domains (CitationRhei et al 1997; CitationMarsh et al 1998; CitationWaite and Eng 2002). Loss of PTEN is also prevalent in sporadic breast cancer, although mutation of the gene is infrequent and methylation of the PTEN promoter is responsible for inhibiting PTEN gene expression (CitationKhan et al 2004). Although PTEN is involved in regulation of the P13K/AKT/mTOR pathway in breast carcinogenesis, recent evidence suggests that its regulation is more complex (CitationdeGraffenried et al 2004; CitationPanigrahi et al 2004; CitationBose et al 2006).
PTEN and the P13K/AKT/mTOR pathway provide useful targets for developing robust therapies for breast cancer (CitationLu et al 2003; CitationKim et al 2005). There has been little work done to target PTEN until recently. Reconstitution studies with PTEN gene therapy in a mouse model for lung cancer, for example, reveals that apoptosis is increased, while AKT and mTOR activation is decreased significantly (CitationKim et al 2005). In addition, antisense oligonucleotides to PTEN resulted in trastuzumab resistance, while rescue of PTEN through P13K inhibitors restored trastuzumab sensitivity (CitationNagata et al 2004). Recently, Par-4 has been shown to participate in PTEN-mediated apoptosis and may provide a useful target for therapeutic development (CitationGoswami et al 2006).
A number of inhibitors have been developed to key components of the P13K/AKT/mTOR pathway (CitationChen et al 2005; CitationGranville et al 2006). P13K inhibitors target the p110 ATP binding site in the catalytic pocket. The two best known inhibitors are LY294002 and wortmannin, which in combination is more effective than either alone and exhibits fewer toxicities. AKT inhibitors exhibit a variety of mechanisms, including translocation inhibition and binding to the catalytic or substrate binding sites. Examples of these inhibitors include perifosine, PX-316, and NL-71-101. The most studied inhibitors are those for mTOR and include rapamycin and its derivatives CCI-779, RAD-001, and AP-23573 (CitationVignot et al 2005; CitationTsang et al 2007). Phase II trials with CCI-779 demonstrated its safety for treating advanced and metastatic breast cancer (CitationChan et al 2002). Recently, a multicenter randomized phase II trial suggests that oral administration of 10 mg daily of RAD-001 is also efficacious in metastatic breast cancer patients (CitationEllard et al 2007).
BRCA1 and BRCA2
The tumor susceptibility genes, BRCA1 and BRCA2, are found in about 80% of familial breast cancer cases and only 5%–10% of all breast cancer cases (CitationRosen et al 2003; CitationAntoniou and Easton 2006). BRCA1 and BRCA2 are considered high-penetrance variants, especially in some ethnic groups like Ashkenazi Jews, with as high as 90% penetrance – although there is evidence to indicate that the estimates over-represent the penetrance by about a half (CitationBegg 2002; CitationMacdonald et al 2004). In general the risk of developing breast cancer increases with age, but due to nongenetic factors the age of onset can vary widely (CitationOsborne et al 2004). However, among those who carry BRCA1 or BRCA2 mutations, the risk of developing cancer not only increases with age but the age of onset is markedly earlier (CitationMacdonald et al 2004). Both BRCA1 and BRCA2 are caretaker genes and are important in maintaining the integrity of the cell’s genome (CitationVenkiteraman 2002; CitationIggvarsson 2004; CitationMacdonald et al 2004).
BRCA1 is located on chromosome 17q21 and contains 24 exons, 22 of which encode for a 220 kDa nuclear phosphoprotein (CitationNathanson et al 2001; CitationMacdonald et al 2004; CitationSchulz 2006). Exon 11 alone accounts for around 50% of the encoding gene. The BRCA1 protein exhibits several structure domains important for its function (CitationRosen et al 2003). At the amino terminus is a zinc-binding RINGfinger domain, containing a cys3-his-cys4 structure, which binds BARD1 (BRCA1-associated RING domain protein) and BAP1 (BRCA1-associated protein) – hallmarks of the RING-finger family of transcriptional regulatory proteins. The domain also binds other proteins, including cyclin D1, ERα, and c-MYC. The carboxy terminus contains two 110 amino acid sequence BRCT (BRCA C terminal) domains that are involved in transcription activation and for binding proteins critical for that function, like histone deactylase. Finally, BRCA1 has a central domain that binds proteins involved in repair of double-strand DNA breaks. BRCA1 mutations are usually frame-shift mutations that result in a truncated protein, but point mutations can occur at both the amino and carboxy termini.
The BRCA1 protein is part of a genome surveillance complex (BASC) that is composed of DNA repair and TSG proteins, such as MSH2 and the RAD50-MRE11-p95 complex, which are involved in recombination-mediated repair of double-stranded DNA breaks (CitationNathanson et al 2001; CitationMacdonald et al 2004; CitationGudmundsdottir and Ashworth 2006). The BRCA 1 gene is transcribed during late G1 phase and throughout the S phase (CitationMacdonald et al 2004). Following DNA damage, ATM, ATR, or CHK2, regulator proteins in pathways of tumor cell suppression, rapidly phosphorylate BRCA1 to an active state (CitationGasco et al 2002; CitationGudmundsdottir and Ashworth 2006). BRCA1 stops the cell cycle at the S and G2/M checkpoints, points before cell division (CitationRosen et al 2003; CitationDeng 2006). In general, BRCA1 inhibits the activity of oncogenes and amplifies the activity of TSGs (CitationRosen et al 2003). For example, it can bind and inhibit c-MYC or it can transactivate both p21 and p27 (CitationRosen et al 2003). BRCA1 can also bind directly to p53, enhancing its transcriptional ability and stabilizing its protein (CitationGasco et al 2002). Finally, it also functions in chromatin remodeling and is required for centromere replication (CitationRosen et al 2003; CitationOsborne et al 2004).
The BRCA2 gene is located on chromosome 13q12 and contains 27 exons, 26 of which encode for a 384 kDa nuclear phosphoprotein (CitationNathanson et al 2001; CitationMacdonald et al 2004; CitationSchulz 2006). Like BRCA1, BRCA2’s exon 11 accounts for half of the coding gene; and, its exon 10 is relatively large compared to other exons. BRCA2 is somewhat structurally similar to BRCA1 but does not contain as many well defined structural domains as BRCA1 (CitationNathanson et al 2001). The amino terminus contains transcriptional activation domains, while the carboxy terminus contains a nuclear localization signal that is involved in shuttling the recombinase RAD51 from the cytoplasm to the nucleus (CitationVenkitaraman 2002; CitationGudmundsdottir and Ashworth 2006). The central domain contains eight copies of the ~40 amino acid BRC repeat, which are responsible for binding RAD51. BRCA1 and BRCA2 are thought to be co-regulated during the cell cycle and DNA repair (CitationRosen et al 2003; CitationMacdonald et al 2004). They, along with RAD51, BARD1 and other components, form the BRCC complex that is critical for double-strand DNA break repair (CitationGudmundsdottir and Ashworth 2006).
The BRCA susceptibility genes afford clinical investigators several strategies for targeted therapy (CitationYarden and Papa 2006). One strategy is to target histone deacetylase, which is involved in chromosome integrity. BRCA1, as noted above, binds and regulates the deacetylase from compromising chromosome integrity. Inhibitors to the enzyme would compensate for breast tumors that do not express BRCA1. Another strategy is to inhibit poly(ADP-ribose) polymerase 1 (PARP1), an enzyme involved in repair of breaks in DNA. Recent studies demonstrate that breast cancer cells deficient in BRCA genes are three orders of magnitude more sensitive than normal breast cells to PARP1 inhibitors, resulting in the induction of cell programmed death because chromosomal DNA breaks are not repaired (CitationBryant et al 2005; CitationFarmer et al 2005; CitationTurner et al 2005).
The next strategy focuses on BRCA replacement gene therapy. Studies have shown that reintroduction of BRCA genes into breast cancer cells have resulted in cell cycle arrest and apoptosis (CitationOsborne et al 2004; CitationStoff-Khalili et al 2006). Another strategy involves BRCA1 overexpression in a breast cancer cell line, which confers resistance to chemotherapy. Utilization of BRCA1 antisense oligonucleotides restored drug sensitivity (CitationHusain et al 1998). Finally, second generation platinum-based chemotherapeutics is being actively perused to treat cancer patients (CitationKelland 2007). For example, a phase II clinical trial with carboplatin is currently underway (CitationBRCA trial 2007).
Challenges
The challenges for the genetic approach to breast cancer involve both greater understanding of the underlying molecular mechanisms for breast carcinogenesis and more effective and specific treatment regimes, as well as prevention of the disease. As for the underlying molecular mechanism, a fuller understanding of the pathways and of the genes that constitute those pathways are required. For example, ten genes have been identified for inherited breast cancer cases; but, they only account for 50% of the cases (CitationWalsh and King 2007). The genes responsible for the other half of inherited breast cancer cases are unresolved. Another important factor for understanding breast cancer development is the tumor’s microenvironment, which also plays a significant role in tumor initiation and progression (CitationLiotta and Kohn 2001; CitationWiseman and Werb 2002). The microenvironment is no longer considered an “innocent bystander” that passively serves as scaffolding for carcinogenesis (CitationErickson and Barcellos-Hoff 2003). Rather, an altered microenvironment or terrain is a common feature of cancer and it is thought to induce malignant transformation of the surrounding epithelium through oncogenic pathways (CitationComoglio and Trusolino 2005). These “landscaper” defects reflect alterations in genes responsible for the microenvironment’s composition and architecture (CitationKinzler and Vogelstein 1998; CitationAlessandro et al 2004).
CitationChow et al (2006) have identified three challenges for breast cancer therapy research. The first involves the improvement of the efficacy for conventional chemotherapy. Especially the use of combinatorial strategies is required to optimize a therapeutic regime, and yet keep toxicities at a minimum. The next challenge is to develop targeted therapeutic protocols for many of the known genes responsible for breast cancer development, especially in terms of gene therapy, and to incorporate them into present protocols or to develop new ones. Moreover, what is required is not an additive but a synergistic effect between different drugs. Such synergism insures that the therapeutic protocol is optimally effective and minimally harmful to the patient. The development of cancer is a complex phenomenon that requires a number of genes and molecular pathways. In essence, the disease is a synergistic interplay of genes and pathways and only a combination of drugs that targets these genes and pathways will be effective. It is doubtful if there is a “magic bullet” therapy for many types of cancer, including breast cancer. In addition, there is the need for the discovery of new genes and genes products to target for therapeutic regimes. The final challenge is the development of better methods for categorizing breast cancer heterogeneity, as well as better means to predict drug response and resistance. Pharmacogenetics and DNA microarray analysis are already being employed to provide more accurate classification of breast cancer types and response of patients to drugs (CitationLønning et al 2005; CitationEspinosa et al 2006; CitationMarsh and McLeod 2007).
Besides these challenges there are two additional ones: cancer stem cells (CSCs) and prevention. Although the idea of CSCs is an old one it has only been within the past decade that it has been supported experimentally (CitationClarke et al 2006; CitationDean 2006; CitationMassard et al 2006; CitationWitcha et al 2006), even though there are some theoretical and technical concerns in terms of its application to solid tumors like breast cancer (CitationHill 2006). The traditional stochastic model claims that any cell can become tumorigenic, while the hierarchical model or cancer stem cell hypothesis claims that only a subset of tumor-initiating cells is responsible for tumorigensis (CitationDick 2003). The cancer stem cell hypothesis has important implications for therapy. Instead of treating proliferating cells, which can only result in limited tumor remission with possible recurrence, elimination of the CSCs would effectively remove the cancer. Recently CSCs, representing about 2% of the cells, were isolated from human breast cancer tissue and produced tumors upon injection into immunodeficient mice (CitationAl-Hajj et al 2003). Moreover, these cells have been grown in vitro (CitationPonti et al 2005, Citation2006). The challenge for breast cancer treatment is to target breast CSCs and their unique components thereby permitting their complete destruction.
The second challenge for breast cancer research is prevention in terms of medical management for early onset of the disease and with respect to lifestyle factors. Medical management vis-à-vis prevention, especially of inherited breast cancer, includes procedures such as early detection of breast cancer by imaging techniques, chemoprevention, and prophylactic surgical procedures (CitationPruthi et al 2007; CitationRobson and Offit 2007). Early detection of breast cancer is important in terms of its prevention, especially since it metastasizes rather quickly. Although the sensitivity of traditional mammography is around 85%, it is not as sensitive (38%–55%) for women with dense breasts or BRCA mutations (CitationKerlikowske et al 1996; CitationScheuer et al 2002; CitationPruthi et al 2007). This means that there is still a considerable number of false negatives, even for traditional imaging techniques. Although new imaging technology is being developed, such as digital mammography, ultrasound, and MRI, appropriate clinical trials have yet to be conducted to test them (CitationElmore et al 2007).
A number of prospective, randomized, placebo-controlled clinical trials have been conducted recently in terms of chemoprevention, especially with the first-generation SERM tamoxifen and the second-generation SERM raloxifene (CitationCuzick et al 2003; CitationVogel 2007). The results from these studies, although encouraging, have been mixed. From the four trials, Royal Marsden, NSBP P-1, Italian, and IBIS-I, the total number of breast cancers developed from the tamoxifen-treated group was 289 out of 14,192 woman, while for the placebo-controlled group it was 465 out of 14,214 women. This represents an average of 38% for the reduction of breast cancer incidence, with a range from 17%–49%. The STAR study, which was recently completed, compared tamoxifen to raloxifene and found that the second-generation SERM was as effective as the first generation SERM and exhibited less pronounced side effects like bone fractures and thromboemboli. Aromatase inhibitors (AIs) are currently being tested in two international clinical trials (CitationO’Regan 2006). The use SERMs or AIs are effective against the incidence of ER-positive breast tumors. Future research must address the prevention of ER-negative tumors.
Besides chemoprevention, surgical procedures have been also developed to prevent the incidence of breast cancer in high risk women, especially BRCA mutation carriers. The first is bilateral prophylactic or risk-reducing mastectomy. The PROSE study found that this surgical procedure reduced the risk of breast cancer by 90% for women with intact ovaries and by 95% for women without ovaries (CitationRebbeck et al 2004). To date, there has not been a randomized controlled clinical trial to confirm the benefit of the procedure (CitationZakaria and Degnim 2007). The major problem with this procedure is its acceptance among high risk women, which requires sociological and psychological studies (CitationLynch et al 2001). Another more acceptable surgical procedure – because of self-image issues – is prophylactic or risk-reducing salpingo-oophorectomy, which reduces the risk of breast cancer by about 50% (CitationKauff and Barakat 2007). The major problem with this procedure is the use of hormones to manage post salpingo-oophorectomy, which may increase the risk of breast cancer incidence.
Lifestyle factors, including body size and composition, diet, and exercise, are important factors in breast cancer prevention (CitationBrody et al 2007; CitationMichels 2007). For example, maintaining one’s “ideal” body weight (BMI = 19–25 kg/m2) and engaging in moderate exercises reduces the risk of breast cancer by about 30% (CitationPruthi et al 2007). Interestingly, diet, especially in terms of a low-fat and high in vegetables, fruit, and fiber diet, does not reduce the risk of breast cancer for women with treated early-stage breast cancer (CitationPierce et al 2007). However, the role of diet on the incidence of breast cancer requires further investigation with respect to long term studies, especially for women who are at risk for the disease. In addition, even though alcohol consumption, cigarette smoking, and exposure to environmental carcinogens are known risk factors for breast cancer, there is still much that needs to be investigated in terms of lower risk patients. In conclusion, although the nature of breast cancer is better understood today than several decades ago there is still much more basic and clinical research needed before the disease is controlled and hopefully someday eradicated.
References
- AdjeiAADyGKErlichmanC2003A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancerClin Cancer Res91152312538459
- AkliSKeyomarsiK2003Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapyCancer Biol Ther2Suppl 1S384714508079
- AkliSKeyomarsiK2004Low-molecular-weight cyclin E: the missing link between biology and clinical outcomeBreast Cancer Res61889115318923
- AlessandroRClairTLiottaLAAbeloffMDArmitageJONiederhuberJE2004The cellular microenvironmentClinical oncology3rd edPhiladelphia, PAElsevier Churchill Livingstone4758
- Al-HajjMWichaMSBenito-HernandezA2003Prospective identification of tumorigenic breast cancer cellsProc Natl Acad Sci USA1003983812629218
- AltundagKIbrahimNK2006Aromatase inhibitors in breast cancerOncologist115536216794235
- AntoniouACEastonDF2006Models of genetic susceptibility to cancerOncogene25589890516998504
- ArnoldAPapanikolaouA2005Cyclin D1 in breast cancer pathogenesisJ Clin Oncol2342152415961768
- BakerSJ2007PTEN enters the nuclear ageCell12825817218252
- BangeJZwickEUllrichA2001Molecular targets for breast cancer therapy and preventionNat Med75485211329054
- BaselgaJPerezEAPienkowskiT2006Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancerOncologist11Suppl 141216971734
- BassoADMirzaALiuG2005The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activityJ Biol Chem28031101816006564
- BazleyLAGullickWJ2005The epidermal growth factor receptor familyEndocr Relat Cancer12S172716113093
- BeggCB2002On the use of familial aggregation in population-based case probands for calculating penetranceJ Natl Cancer Inst941221612189225
- BerglundPLandbergG2006Cyclin E overexpression reduces infiltrative growth in breast cancer: yet another link between proliferation control and tumor invasionCell Cycle5606916582601
- BernsEMJJFoekensJAvan StaverenIL1995Oncogene amplification and prognosis in breast cancer; relationship and systemic treatmentGene1591187607564
- BiancoRCiardielloFTortoraG2005Chemosensitization by antisense oligonucleotides targeting MDM2Curr Cancer Drug Targets551615720189
- BiècheILidereauR2000Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancerMol Carcinog29151811108660
- Børresen-DaleAL2003TP53 and breast cancerHum Mutat2129230012619115
- BoscoEEWangYXuH2007The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancerJ Clin Invest1172182817160137
- BoseSChandranSMirochaJM2006The Akt pathway in human breast cancer: a tissue-array-based analysisMod Pathol192384516341149
- BossiGSacchiA2007Restoration of wild-type p53 function in human cancer: relevance for tumor therapyHead Neck292728417230559
- BouchetBPde FromentelCCPuisieuxA2006p53 as a target for anti-cancer drug developmentCrit Rev Oncol Hematol5819020716690321
- BoveriT1914Zur Frage der Entstehung maligner TumorenJenaFischer
- BRCA Trial2007A randomized phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancerAccessed 9 August 2007 URL: http://www.geneticbreastcancertrial.usilu.net/Home.asp
- BraithwaiteAWRoydsJAJacksonP2005The p53 story: layers of complexityCarcinogenesis261161915817608
- BrodyJGRudelRAMichelsKB2007Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for preventionCancer10926273417503444
- BryantHESchultzNThomasHD2005Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature4349131715829966
- BurrisHAIII2004Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinibOncologist9Suppl 310515163842
- ButtAJMcNeilCMMusgroveEA2005Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin EEndocr Relat Cancer12S475916113099
- BykovVJZacheNStridhH2005PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosisOncogene1234849115735745
- CaldonCEDalyRJSutherlandRL2006Cell cycle control in breast cancer cellsJ Cell Biochem972617416267837
- CarrollJSSwarbrickAMusgroveEA2002Mechanism of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of estrogensCancer Res6231263112036924
- ChanSJohnsonSScheulenM2002First report: a phase II study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapyProc Am Soc Clin Oncol2144a
- ChanSKHillMEGullickWJ2006The role of the epidermal growth factor receptor in breast cancerJ Mammary Gland Biol Neoplasia1131116947082
- ChanoTKontaniKTeramotoK2002Truncating mutations of RB1CC1 in human breast cancerNat Genet31285812068296
- ChauBNPanCWWangJYJ2006Separation of anti-proliferation and anti-apoptotic functions of retinoblastoma protein through targeted mutations of its A/B domainPLoS ONE1e8217183714
- ChenYLLawPYLohHH2005Inhibition of P13K/Akt signaling: an emerging paradigm for targeted cancer therapyCurr Med Chem Anticancer Agents55758916305480
- ChowLWCYiuCCPYipAYS2006The future perspectives of breast cancer therapyBiomed Pharmacother602596216824726
- ChristensenLAFinchRABookerAJ2006Targeting oncogenes to improve breast cancer chemotherapyCancer Res6640899416618728
- ChungJHOstrowskiMCRomighT2006The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulationHum Mol Genet152553916849370
- ClarkGJDerCJ1995Aberrant function of the Ras signal transduction pathway in human breast cancerBreast Cancer Res Treat35133447612899
- ClarkeMFDickJEDirksPB2006Cancer stem cells – perspective on current status and future directions: AARC workshop on cancer stem cellsCancer Res6693394416990346
- ClaudioPPToniniTGiordanoA2002The retinoblastoma family: twins or distant cousinsGenome Biol319
- CollinsIGarrettMD2005Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitorsCurr Opin Pharmacol53667315964238
- ComoglioPMTrusolinoL2005Cancer: the matrix ix now in controlNat Med1115569
- CoxMCDanTDSwainSM2006Emerging drugs to replace current leaders in first-line therapy for breast cancerExpert Opin Emerging Drugs11489501
- CullenRMaguireTMMcDermottEW2001Studies on oestrogen receptor-alpha and -beta mRNA during in breast cancerEur J Cancer3711182211378342
- CuzickJPowlesTVeronesiU2003Overview of the main outcomes in breast-cancer preventionLancet36129630012559863
- DangCVO’DonnellKAZellerKI2006The c-Myc target gene networkSemin Cancer Biol162536416904903
- D’CruzCMGuntherEJBoxerRB2001c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutationsNat Med7235911175856
- DeanM2006Cancer stem cells: redefining the paradigm of cancer strategiesMol Interv61419
- deGraffenriedLAFulcherLFriedrichsWE2004Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathwayAnn Oncol151510615367412
- DengCX2006BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolutionNucleic Acids Res3414162616522651
- DickJE2003Breast cancer stem cells revealedProc Natl Acad Sci USA1003547912657737
- Di CristofanoADPandolfiPP2000The multiple roles of PTEN in tumor suppressionCell1003879010693755
- DuWPogorilerJ2006Retinoblastoma family genesOncogene25519020016936737
- DysonN1998The regulation of E2F by pRB-family proteinsGenes Dev122245629694791
- EckertLBRepaskyGAÜlküAS2004Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikisCancer Res6445859215231670
- EdlerLKopp-SchneiderA2005Origins of the mutational origin of cancerInt J Epidemiol3411687016046521
- EllardSGelmonKAChiaS2007A randomized phase II study of two different schedules of RAD001C in patients with recurrent/meta-static breast cancerJ Clin Oncol25 abst 3513
- ElmoreJGArmstrongKLehmanCD2007Screening for breast cancerJAMA29312455615755947
- EricksonACBarcellos-HoffMH2003The not-so innocent bystander: the microenvironment as a therapeutic target in cancerExpert Opin Ther Targets7718812556204
- EspinosaERedondoAVaraJÁF2006High-throughput techniques in breast cancer: a clinical perspectiveEur J Cancer4259860716431104
- FarmerHMcCabeNLordCJ2005Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature4349172115829967
- FieldJKSpandidosDA1990The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosisAnticancer Res101222185684
- FosterJSHenleyDCAhamedS2001Estrogens and cell-cycle regulation in breast cancerTrends Endocrinol Metab12320711504672
- FrasorJDanesJMKommB2003Response-specific and ligand dose-dependent modulation of estrogen receptor (ER)α activity by ERβ in the uterusEndocrinology14445627412959972
- FuMWangCLiZ2004Cyclin D1: normal and abnormal functionsEndocrinology14554394715331580
- GaffeyMJFriersonHFJWilliamsME1993Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlationsMod Pathol665497905628
- GaoXLiuF2007New agents in development of breast cancerCurr Opin Obstet Gynecol19687417218855
- GarciaJMSilvaJMDominguezG1999Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotypeBreast Cancer Res Treat572374310617300
- GarrettC2005Targeted therapy: the fast pace of progressCancer Control1271215855889
- GascoMShamiSCrookT2002The p53 pathway in breast cancerBreast Cancer Res470611879567
- GaspariniGLongoRTorinoF2005Therapy of breast cancer with molecular targeting agentsAnn Oncol16Suppl 4iv283615923426
- GeyerCEFosterJLindquistD2006Lapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med35527334317192538
- GiehlK2005Oncogenic Ras in tumor progression and metastasisBiol Chem38619320515843165
- GranvilleCAMemmottRMGillsJJ2006Handikapping the race to develop inhibitors of the phosphoinoside 3-kinase/Akt/mammailian target of rapamycin pathwayClin Cancer Res126798916467077
- GoswamiARanganathanPRangnekarVM2006The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer selective therapeutic agentCancer Res6628899216540633
- GudmundsdottirKAshworthA2006The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stabilityOncogene2558647416998501
- GuerinDASabatiniDM2005An expanding role for mTOR in cancerTRENDS Mol Med113536116002336
- GuerinMBarroisMTerrierMJ1988Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosisOncogene Res321312905033
- HanahanDWeinbergRA2000The hallmarks of cancerCell100577010647931
- HancockJF2003Ras proteins: different signals from different locationsNat Rev Mol Cell Biol43738412728271
- HarrisH2005A long view of fashions in cancer researchBioessays27833816015588
- HarrisRCChungECoffeyRJ2003EGF receptor ligandsExp Cell Res28421312648462
- HarwellRMMullBBPorterDC2004Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cellsJ Biol Chem2791269570514701826
- HauptY2004p53 regulation: a family affairCell Cycle3884515190198
- HayashiSIEguchiHTanimotoK2003The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical applicationEndocr Relat Cancer1019320212790782
- HeadJJohnstonSRD2004New targets for therapy in breast cancer: farnesyltransferase inhibitorsBreast Cancer Res6262815535857
- HenrikssonMLuscherB1996Proteins of the Myc network: essential regulators of cell growth and differentiationAdv Cancer Res68109828712067
- HerynkMHFuquaSAW2004Estrogen receptor mutations in human diseaseEndocr Rev258699815583021
- HewittSCHarrellJCKorachKS2005Lessons in estrogen biology from knockout and transgenic animalsAnnu Rev Physiol6728530815709960
- HillRP2006Identifying cancer stem cells in solid tumors: case not provenCancer Res661891616488984
- HobdayTJPerezEA2005Molecularly targeted therapies for breast cancerCancer Control12738115855890
- HolbroTCivenniGHynesNE2003The erbB receptors and their role in cancer progressionExp Cell Res2849911012648469
- HollestelleAElstrodtFNagelJHA2007Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell linesMol Cancer Res519520117314276
- HuangJKiXHilfR2005Molecular basis of therapeutic strategies for breast cancerCurr Drug Targets Immune Endocr Metabol Disord53799616375692
- HudisCA2007Trastuzumab – mechanism of action and use in clinical practiceN Engl J Med357395117611206
- HuntKKKeyomarsiK2005Cyclin E as a prognostic and predictive marker in breast cancerSemin Cancer Biol153192616043362
- HusainHEGVenkatramanESSpriggsDR1998BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II)Cancer Res58112039515792
- IdekaKInoueS2004Estrogen receptors and their downstream targets in cancerArch Histol Cytol674354315781984
- IngvarssonS2004Genetics of breast cancerDrugs Today40991100215645010
- IsraelsEDIsraelsLG2000The cell cycleOncologist5510311110604
- JamersonMHJohnsonMDDicksonRB2004Of mice and myc: c-myc and mammary tumorigenesisJ Mammary Gland Biol Neoplasia9273715082916
- JemalASiegelRWardE2007Cancer statistics, 2007CA Cancer J Clin57436617237035
- JohnsonMLSeidmanAD2005Emerging targeted therapies for breast cancerOncology19611815945342
- JohnsonDGWalkerCL1999Cyclins and cell cycle checkpointsAnnu Rev Pharmacol Toxicol3929531210331086
- JohnstonSRDHickishTEllisP2003Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancerJ Clin Oncol212492912829668
- JordanVC2007SERMs: meeting the promise of multifunctional medicinesJNCI99350617341726
- JordanVCBrodieAM2007Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancerSteroids7272517169390
- JorissenRNWalkerFPouliotN2003Epidermal growth factor receptor:mechanisms of activation and signallingExp Cell Res284315312648464
- KaklamaniVO’ReganRM2004New targeted therapies in breast cancerSemin Oncol31Suppl 420515124130
- KaptainSTanLKChenB2001Her-2/neu and breast cancerDiagn Mol Pathol101395211552716
- KauffNDBarakatRR2007Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA 2J Clin Oncol252921717617523
- KellandL2007The resurgence of platinum-based cancer chemotherapyNat Rev Cancer75738417625587
- KenemansRVerstraetenRAVerheijenRHM2004Oncogenic pathways in hereditary and sporadic breast cancerMaturitas49344315351094
- KerlikowskeKGradyDBarclayJ1996Effect of age, breast density, and family history on the sensitivity of first screening mammographyJAMA2763388667536
- KhanSKumagaiTVoraJ2004PTEN promoter is methylated in a proportion of invasive breast cancersInt J Cancer1124071015382065
- KimDChengGZLindsleyCW2005Targeting the phosphatidylinositol-3-kinase/Akt pathway for the treatment of cancerCurr Opin Investig Drugs612508
- KimRHMakTW2006Tumours and tremors: how PTEN regulation underlies bothBr J Cancer94620416495927
- KinzlerKWVogelsteinB1997Gatekeepers and caretakersNature38676129126728
- KinzlerKWVogelsteinB1998Landscaping the cancer terrainScience280103679616081
- KlapperLNKirschbaumMHSelaM2000Biochemical and clinical implications of the erbB/HER signaling network of growth factor receptorsAdv Cancer Res77257910549355
- KnudsenESKnudsenKE2006Retinoblastoma tumor suppressor: where cancer meets the cell cycleExp Biol Med231127181
- KnudsonAGJr1971Mutation and cancer: statistical study of retinoblasatomaProc Natl Acad Sci USA6882035279523
- KonecnyGEPegramMDVenkatesanN2006Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-over-expression and trastuzumab-treated breast cancer cellsCancer Res661630916452222
- KuiperGGEnmarkEPelto-HuikkoM1996Cloning of novel receptor expressed in rat prostrate and ovaryProc Natl Acad Sci USA935925308650195
- LacroixMToillonRALeclercqG2006p53 and breast cancer: an updateEndocr Relat Cancer1329332516728565
- LaneDP1992p53: the guardian of the genomeNature3581561614522
- LebowitzPFEng-WongJWidemannBC2005A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerClin Cancer Res1112475215709195
- LiJYenCLiawD1997PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancerScience275194379072974
- LiaoDJDicksonRB2000c-Myc in breast cancerEndocr Relat Cancer71436411021963
- LiawDMarshDJLiJ1997Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndromeNat Genet166479140396
- LiottaLAKohnEC2001The microenvironment of the tumor-host interfaceNature411375911357145
- LiuTGYinJQShangBY2004Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancerCancer Gene Ther117485615375377
- LodénMStoghallMNielsenNH2002The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb nodeOncogene2146809012096344
- LønningPESørlieTBørresen-DaleAL2005Genomics in breast cancer – therapeutic implicationsNat Clin Prac Oncol22633
- LuYLinYZLaPushinR1999The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cellsOncogene1870344510597304
- LuYWangHMillsGB2003Targeting the P13K-AKT pathway for cancer therapyRev Clin Exp Hematol72052814763163
- LynchHTLynchJFRubinsteinWS2001Prophylactic mastectomy: obstacles and benefitsJ Natl Cancer Inst931586711698554
- MacdonaldFFordCHJCassonAG2004Molecular biology of cancer2nd edLondonBIOS Scientific
- MacleodK2000Tumor suppressor genesCurr Opin Genet Dev10819310679386
- MaehamaTDixonJE1999PTEN: a tumour suppressor that functions as a phospholipid phosphataseTrends Cell Biol9125810203785
- MagnificoAAlbanoLCampanerS2007Protein kinase Cα determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplificationCancer Res6753081717545611
- MalumbresM2005Revisiting the “cdk-centric” view of the mammalian cell cycleCell Cycle42061015655365
- MarcumJABurnsCRO’NeillYVAlbouP2002The transformation of oncology in the twentieth century: the molecularization of cancerProceedings of the 37th International Congress on the History of MedicineGalveston, TXUniversity of Texas Medical Branch419
- MarcusAIZhouJO’BrateA2005The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylaseCancer Res6538839315867388
- MargolinSLindblomA2006Familial breast cancer, underlying genes, and clinical implications: a reviewCrit Rev Oncog127511317078207
- MarshDJCoulonVLunettaKL1998Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutationHum Mol Genet7507159467011
- MarshSMcLeodHI2007Pharmacogenetics and oncology for breast cancerExpert Opin Pharmacother81192717257083
- MassardCDeutschESoriaJC2006Tumour stem cell-targeted treatment: elimination or differentiationAnn Oncol171620416600978
- Meric-BernstamFHungMC2006Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapyClin Cancer Res1263263017085641
- MessinisIE2006From menarche to regular menstruation: endocrinological backgroundAnn N Y Acad Sci1092495617308132
- MichelsKBMohllajeeAPRoset-BahmanyarE2007Diet and breast cancer: a review of the prospective observational studiesCancer10927124917503428
- MorganDO1997Cyclin-dependent kinases: engines, clocks, and microprocessorsAnnu Rev Cell Dev Biol13261919442875
- MöröyTGeisenC2004Cyclin EInt J Biochem Cell Biol3614243915147722
- MorrisEJDysonNJ2001Retinoblastoma protein partnersAdv Cancer Res8215411447760
- MotoyamaNNakaK2004DNA damage tumor suppressor genes and genomic instabilityCurr Opin Genet Dev1411615108799
- MouridesenHGershanovichMSunY2003Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupJ Clin Oncol212101912775735
- MoyBGossPE2006Lapatinib: current status and future directions in breast cancerOncologist1110475717110623
- MurrayAW2004Recycling the cell cycle: cyclins revisitedCell1162213414744433
- MussHB2006Targeted therapies for metastatic breast cancerN Engl J Med3552783517192546
- NagataYLanKHZhouX2004PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell61172715324695
- NahtaREstevaFJ2007Trastuzumab: triumphs and tribulationsOncogene2636374317530017
- NassSJDicksonRB1997Defining a role for c-Myc in breast tumorigenesisBreast Cancer Res Treat441229164674
- NathansonKLWoosterRWeberBL2001Breast cancer genetics: what we know and what we needNat Med7552611329055
- OesterreichSFuquaSAW1999Tumor suppressor genes in breast cancerEndocr Relat Cancer64051910516854
- OliveiraAMRossJSFletcherJA2005Tumor suppressor genes in breast cancer: the gatekeepers and the caretakersAm J Clin Pathol124Suppl 1S162816468415
- O’ReganRMKhuriFR2004Farnesyl transferase inhibitors: the next targeted therapies for breast cancerEndocr Relat Cancer1119120515163298
- O’ReganRM2006Chemoprevention of breast cancerLancet3671382316650636
- OsborneCWilsonPTripathyD2004Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applicationsOncologist93617715266090
- OsterSKHoCSWSoucieEL2002The myc oncogene: MarvouslY ComplexAdv Cancer Res848115411885563
- PanigrahiARPinderSEChanSY2004The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcomeJ Pathol2049310015307142
- ParkMTLeeSJ2003Cell cycle and cancerJ Biochem Mol Biol3660512542976
- PavelićKGall-TrošeljK2001Recent advances in molecular genetics of breast cancerJ Mol Med795667311692153
- PegramMDPietrasRBajamondeA2005Targeted therapy: wave if the futureJ Clin Oncol2317768115755985
- PelengarisSKhanM2003The many faces of c-MYCArch Biochem Biophys4161293612893289
- PerouCMSørlieTElsenMB2000Molecular portraits of human breast tumorsNature4067475210963602
- PetrocelliTSlingerlandJM2001PTEN deficiency: a role in mammary carcinogenesisBreast Cancer Res33566011737885
- Piccart-GebhartMJ2006Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learnEur J Cancer421715916806901
- PierceJPNatarajanLCaanBJ2007Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trialJAMA2982899817635889
- PontiDCostaAZaffaroniN2005In vitro propagation of breast tumorigenic cancer cells with stem/progenitor cell propertiesCancer Res6555061115994920
- PontiDZaffaroniNCapelliC2005Breast cancer cells: an overviewEur J Cancer4212192416624548
- PruthiSBrandtKRDegnimAC2007A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosisMayo Clin Proc82999101217673070
- RebbeckTRFriebelTLynchHT2004Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study groupJ Clin Oncol2210556214981104
- RheiEKangLBogomolniyF1997Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomasCancer Res57365799288766
- RobsonMOffitK2007Management of an inherited predisposition to breast cancerN Eng J Med35715462
- RochefortHGlonduMSahlaME2003How to target estrogen receptor-negative breast cancerEndocr Relat Cancer10261612790787
- RosenEMFanSPestellRG2003BRCA1 gene in breast cancerJ Cell Physiol196194112767038
- RossJSFletcherJA1998The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapyStem Cells16413289831867
- RossJSFletcherJALinetteGP2003The HER-2/neu gene and protein in breast cancer 2003: biomarkers and target of therapyOncologist83072512897328
- RossJSFletcherJABloomKJ2004aTargeted therapy in breast cancer: the HER-2/neu gene and proteinMol Cell Proteomics33799814762215
- RossJSLinetteGPStecJ2004bBreast cancer biomarkers and molecular medicineExpert Rev Mol Diagn41698814995904
- RoyPGThompsonAM2006Cyclin D1 and breast cancerBreast157182716675218
- RussoJRussoIH2006The role of estrogen in the initiation of breast cancerJ Steroid Biochem Mol Biol102899617113977
- RyanKMBirnieGD1996Myc oncogenes: the enigmatic familyBiochem J314713218615760
- SánchezIDynlachtBD2005New insights into cyclins, CDKs, and cell cycle controlSemin Cell Dev Biol163112115840440
- SandalT2002Molecular aspects of the mammalian cell cycle and cancerOncologist7738111854549
- SchaferKA1998The cell cycle: a reviewVet Pathol35461789823588
- ScheuerLKauffNRobsonM2002Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriersJ Clin Oncol201260811870168
- SchulzWA2006Molecular biology of human cancers an advanced student’s textbookDordrechtSpringer
- SeegerHWallwienerDMueckAO2003Statins can inhibit proliferation of human breast cancer cells in vitroExp Clin Endocrinol Diabetes11147812605351
- SegotaEBukowskiRM2004The promise of targeted therapy: cancer drugs become more specificCleve Clin J Med715516015320364
- SenderowiczAM2003Small-molecular cyclin-dependent kinase modulatorsOncogene2266092014528286
- SeynaeveCVerweijJ2004Targeted therapy: ready for prime timeCancer Treat Res12011515217215
- SharkeyRMGoldenbergDM2006Targeted therapy of cancer: new prospects of antibodies and immunoconjugatesCA Cancer J Clin562264316870998
- SherrCJ1996Cancer cell cyclesScience274167278939849
- SherrCJ2000Cancer cell cycle revisitedCancer Res6036899510919634
- SherrCJ2004Principles of tumor suppressionCell1162354614744434
- SherrCJRobertsJM1999CDK inhibitors: positive and negative regulators of G1-phase progressionGenes Dev1315011210385618
- SherrCJRobertsJM2004Living with and without cyclins and cyclin-dependent kinasesGenes Dev18269971115545627
- ShinIKimSSongH2005H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cellsJ Biol Chem280146758315677464
- SiminKWuHLuL2004pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epitheliaPLoS Biol2194205
- SimpsonLParsonsR2001PTEN: life as a tumor suppressorExp Cell Res264294111237521
- SledgeGWJr2001Breast cancer in the clinic: treatments past, treatments futureJ Mammary Gland Biol Neoplasia64879512013537
- SledgeGWJr2005What is targeted therapyJ Clin Oncol231614515755966
- SledgeGWJrMillerKD2003Exploiting the hallmarks of cancer: the future conquest of breast cancerEur J Cancer3916687512888360
- SoosTJParkMKiyokawaH1998Regulation of the cell cycle by CDK inhibitorsResults Probl Cell Differ22111319670321
- StevensonLERavichandranKSFrackeltonARJr1999Shc dominant negative disrupts cell cycle progression in both G0-G1 and G2-M of ErbB2-positive breast cancer cellsCell Growth Differ1061719950219
- Stoff-KhaliliMADallPCurielDT2006Gene therapy for carcinoma of the breastCancer Gene Ther136334716410823
- SuiGSoohooCAffarEB2002A DNA vector-based RNAi technology to suppress gene expression in mammalian cellsProc Natl Acad Sci USA9955152011960009
- SunpaweravongSSunpaweravongP2005Recent developments in critical genes in the molecular biology of breast cancerAsian J Surg2871515691805
- SutherlandRLMusgroveEA2004Cyclins and breast cancerJ Mammary Gland Biol Neoplasia99510415082921
- TakimotoRWangWDickerDT2002The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 proteinCancer Biol Ther1475512174820
- TamuraMGuJTranH1999PTEN gene and integrin signaling in cancerJ Natl Cancer Inst911820810547389
- ToledoFWahlGM2006Regulating the p53 pathway: in vitro hypothesis, in vivo veritasNat Rev690923
- ToveySMReevesJRStantonP2006Low expression of HER2 protein in breast cancer is biologically significantJ Pathol2103586216981252
- TripathyD2005Targeted therapies in breast cancerBreast J11Suppl 1S30515725114
- TsangCKQiHLiuLF2007Targeting mammalian target of rapamycin (mTOR) for health and diseaseDrug Discov Today121122417275731
- TurnerNTuttAAshworthA2005Targeting the DNA repair defect in BRCA tumoursCurr Opin Pharmacol53889315955736
- TysonJJCsikasz-NagyANovakB2002The dynamics of cell cycle regulationBioEssays241095110912447975
- VarmusHWeinbergRA1993Genes and the biology of cancerNew YorkScientific American Library
- VenkitaramanAR2002Cancer susceptibility and the functions of BRCA1 and BRCA2Cell1081718211832208
- VermeulenKvan BockstaeleDRBernemanZN2003The cell cycle: a review of regulation, deregulation and therapeutic targets in cancerCell Prolif361314912814430
- VignotSFaivreSAguirreD2005mTOR-targeted therapy of cancer with rapamycin derivativesAnn Oncol165253715728109
- VogelVG2007Chemoprevention strategies 2006Curr Treat Options Oncol8748817634835
- VogelsteinBKinzlerKW2004Cancer genes and the pathways they controlNat Med107899915286780
- von LintigFCDreilingerADVarkiNM2000Ras activation in human breast cancerBreast Cancer Res Treat62516210989985
- WaiteKAEngC2002Protean PTEN: form and functionAm J Hum Genet708294411875759
- WalshTKingMC2007Ten genes for inherited breast cancerCancer Cell11103517292821
- WalsheJMDenduluriNBermanAW2006A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancerClin Breast Cancer6535916595039
- WangWRastinejadFEl-DeiryWS2003Restoring p53-dependent tumor suppressionCancer Biol Ther2Suppl 1S556314508081
- WangYLiuSZhangG2005Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivoBreast Cancer Res7R220815743499
- WärnbergFWhiteDAndersonE2006Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivoBreast Cancer Res82R213016611371
- WatsonPHPonRTShiuRPC1991Inhibition of c-myc expression by phophorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancerCancer Res51399640001855215
- WeinbergRA1998One renegade cell: how cancer beginsNew YorkBasic Books
- WengLPSmithWMDahiaPLM1999PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell deathCancer Res5958081410582703
- Węsierska-GądekJGueorguievaMHorkyM2003Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis: a comparison of the effects exerted by roscovitine and cisplatinPol J Pharmacol5589590214704484
- WhyteP1995The retinoblastoma protein and its relativesSemin Cancer Biol683907647310
- WichaMSLiuSDontuG2006Cancer stem cells: an old idea – a paradigm shiftCancer Res6618839016488983
- WisemanBSWerbZ2002Stromal effects on mammary gland development and breast cancerScience2961046912004111
- WittonCJReevesJRGoingJJ2003Expression of the HER1-4 family of receptor tyrosine kinases in breast cancerJ Pathol200290712845624
- WrenBG2004Do female sex hormones initiate breast cancer? A review of the evidenceClimacteric7120815497900
- WunderlichV2006Early references to the mutational origin of cancerInt J Epidemiol1412
- YangDCElliotRLHeadJF2002Gene targets of antisense therapies in breast cancerExpert Opin Ther Targets63758512223074
- YangSPSongSTSongHF2003Advancements of antisense oligonucleotides in treatment of breast cancerActa Pharmacol Sin242899512676065
- YardenRIPapaMZ2006BRCA1 at the crossroads of multiple cellular pathways: approaches for therapeutic interventionsMol Cancer Ther5139640416818497
- ZakariaSDegnimAC2007Prophylactic mastectomySurg Clin North Am873173117498529
- ZhengLLeeWH2001The retinoblastoma gene: a prototypic and multifunctional tumor suppressorExp Cell Res26421811237519